IL10 and colitis: Although infliximab protected IL-10−/− mice from loss of body weight, shortening of colon lengths and production of excessive pro-inflammatory cytokines and mitigated the histological signs of colitis in colon sections, its therapeutic effect was inferior to the CMV-siRT+B+I circuit (Fig. 9a–g).